Hispec will invest 10 million US dollars in pneuma restaurant and reach a distribution agreement

August 13, 2018 / Meitong news agency / -- the first breathing digital inhaler (BDI) pneumahaler has been developed Gamma According to pneuma pharmaceutical, Inc., a Chinese company specializing in research and development and sales of therapeutic drugs, HISCO Pharmaceutical Group has agreed to invest $10 million in pneuma pharmaceutical As part of the agreement, HISCO Pharmaceutical Group will obtain the right to distribute pharmaceutical products of pneuma pharmaceutical in China HISCO will be responsible for funding regulatory applications in China Pneuma restaurant, Inc ("pneuma") has developed pneumahaler Gamma The breathing digital inhaler can solve the problems of the existing metered dose, dry powder and soft mist inhalers, so as to improve the efficacy of the existing airway drugs Pneumahaler BDI ("pneumahaler") is the first lung inhaler that combines advanced droplet jet technology with digital controlled breathing technology, packaged in a small, lightweight device The marketing strategy of pneuma is to combine its digital platform technology with non patent drugs to create more effective treatment methods for asthma and chronic obstructive pulmonary disease Pneuma's strategy is to reduce the risk of its clinical and regulatory pathways by rebranding its non proprietary treatment brand within its patented pneumahaler system, and to create value to improve inhalation treatment outcomes for patients in the global market for asthma and COPD worth more than $39 billion Eric hunter, CEO and co-founder of pneuma restaurant, said: "we are looking forward to working with Hisense to launch pharmaceutical products of pneuma in China As a well-known pharmaceutical company in China, this investment is a trust in our team and our approach to improving the effectiveness of drugs " About pneuma restaurant, founded in 2015, is a pharmaceutical company headquartered in Boone, North Carolina With the help of a global team of researchers, doctors, designers and engineers, pneuma created pneumahaler Gamma This is the first fully integrated digital breathing inhaler The inhaled drug delivery system has integrated Bluetooth technology to provide drug delivery feedback to patients, family members and medical service providers With pneuma's (proprietary / patented) digital droplet ejector technology, pneuma's equipment, although currently only available for research purposes, may eventually provide a range of new therapies, including biological agents, to the lungs.